Dr. Bing Xu: Understanding and Conquering IVLBCL—Progress in Diagnosis and Treatment | 2024 Northern Hematology and Oncology Immunotherapy Conference

Dr. Bing Xu: Understanding and Conquering IVLBCL—Progress in Diagnosis and Treatment | 2024 Northern Hematology and Oncology Immunotherapy Conference

2024.08.26
Intravascular large B-cell lymphoma (IVLBCL) is a rare form of non-Hodgkin lymphoma with atypical clinical presentations, leading to high rates of misdiagnosis and missed diagnosis in clinical practice. There is an urgent need to improve the current status of diagnosis and treatment. Recently, the "2024 Northern Hematology and Oncology Immunotherapy Conference," hosted by the Tianjin Society of Hematology and Regenerative Medicine, was held grandly in the northern coastal city of Tianjin. The conference brought together renowned hematology experts from across the country, focusing on the immunotherapy of hematologic malignancies. They explored the latest advances in the diagnosis and treatment of various hematologic sub-specialties, the pathogenesis of hematologic tumors, and progress in immunotherapy. At the conference, Dr. Bing Xu from The First Affiliated Hospital of Xiamen University delivered an outstanding report titled "Advances in the Diagnosis and Treatment of Intravascular Large B-Cell Lymphoma—Interpretation of the 2023 Chinese Expert Consensus," providing crucial guidance for comprehensively understanding and recognizing this disease. Hematology Frontier invited Dr. Bing Xu to share further insights on this topic.
Dr. Jun Shi: Ongoing Exploration to Optimize First-Line Treatment for Non-Gastric MALT Lymphoma | 2024 Northern Hematology and Oncology Immunotherapy

Dr. Jun Shi: Ongoing Exploration to Optimize First-Line Treatment for Non-Gastric MALT Lymphoma | 2024 Northern Hematology and Oncology Immunotherapy

2024.08.26
While radiotherapy is the recommended first-line treatment for mucosa-associated lymphoid tissue (MALT) lymphoma, for certain non-gastric MALT lymphomas in specific locations, radiotherapy may result in significant side effects that can affect patients' quality of life. Recently, the "2024 Northern Hematology and Oncology Immunotherapy Conference," hosted by the Tianjin Society of Hematology and Regenerative Medicine, was held grandly in the northern coastal city of Tianjin. The conference brought together renowned hematology experts from across the country, focusing on the immunotherapy of hematologic malignancies. They explored the latest advances in the diagnosis and treatment of various hematologic sub-specialties, the pathogenesis of hematologic tumors, and progress in immunotherapy. At the conference, Dr. Jun Shi from Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, delivered an insightful presentation titled "Treatment Options for Localized Non-Gastric MALT Lymphoma," offering valuable guidance for optimizing the treatment of this disease. Hematology Frontier invited Dr. Jun Shi to further discuss this topic.
Dr. Sujun Zheng: From Hepatitis to Liver Cancer – Exploring Comprehensive Management of Liver Diseases

Dr. Sujun Zheng: From Hepatitis to Liver Cancer – Exploring Comprehensive Management of Liver Diseases

2024.08.26
HBV infection is a major cause of chronic hepatitis B (CHB), cirrhosis, liver failure, and hepatocellular carcinoma. Despite the development of new drugs and advancements in antiviral therapy, a complete cure for CHB remains a clinical challenge. The burden of liver disease in China is still heavy, and the implementation of high-quality liver disease management is urgently needed. This involves a comprehensive approach that includes enhanced public education, convenient screening and monitoring, empowerment of primary healthcare, optimization of doctor incentives, refined data management, and scientifically sound prevention and treatment strategies. Recently, Dr. Sujun Zheng from Beijing You An Hospital, Capital Medical University, provided a systematic overview of the exploration and progress in comprehensive liver disease management during an academic exchange. The following is a summary of the key points shared.
Showcasing Chinese Wisdom on the International Stage: The 25th International AIDS Conference, China Special Session

Showcasing Chinese Wisdom on the International Stage: The 25th International AIDS Conference, China Special Session

2024.08.26
From July 22-26, 2024, the 25th International AIDS Conference (AIDS 2024) was held in Munich, Germany. As a key player in the global fight against AIDS, China has consistently made significant contributions. At this conference, the China Special Session, titled "Ending AIDS in China: Challenges and Strategies," was jointly organized by the Chinese Association of STD and AIDS Prevention and Control, the Chinese Center for Disease Control and Prevention AIDS Center, and the Chinese Preventive Medicine Association. This session not only highlighted China's achievements in HIV/AIDS prevention and control but also explored the challenges ahead and the future direction of global AIDS prevention, providing new insights and momentum for the worldwide fight against AIDS.
Voice of China in AIDS Research丨Dr. Fujie Zhang’s Team: Efficacy of Long-term Antiretroviral Therapy in Chinese Children and Adolescents with HIV

Voice of China in AIDS Research丨Dr. Fujie Zhang’s Team: Efficacy of Long-term Antiretroviral Therapy in Chinese Children and Adolescents with HIV

2024.08.26
From July 22-26, 2024, the 25th International AIDS Conference took place in Munich, Germany, gathering 15,000 professionals and advocates from around the world to discuss the latest advancements and future challenges in AIDS prevention and treatment. At the conference, Dr. Hanxi Zhang from Dr. Fujie Zhang’s team at Beijing Ditan Hospital presented a multicenter, prospective, longitudinal cohort study conducted in China, which garnered widespread attention. Led by Beijing Ditan Hospital, Capital Medical University, this study aimed to evaluate the impact of antiretroviral therapy (ART) on mortality and virologic response in children and adolescents with HIV. The findings provided valuable insights into the long-term efficacy of ART in Chinese children living with HIV, indicating significant achievements of the ART program in this demographic. We invited Dr. Fujie Zhang to offer an in-depth analysis of the study's findings.
2024 CUDA丨Dr. Xiongjun Ye: Mastering the Characteristics and Approaches of Robot-Assisted Partial Nephrectomy, Clarifying the Path to Optimization

2024 CUDA丨Dr. Xiongjun Ye: Mastering the Characteristics and Approaches of Robot-Assisted Partial Nephrectomy, Clarifying the Path to Optimization

2024.08.25
From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi'an. Organized by the Chinese Medical Doctor Association and the Urology Physicians Branch, and hosted by Xijing Hospital of the Air Force Medical University, with support from the Urology Physicians Branch of the Shaanxi Medical Doctor Association, the conference showcased the latest achievements in urology from a broad and multidimensional perspective under the theme "Healthy China, Urology Leads the Way." At the conference, Urology Frontier interviewed Dr. Xiongjun Ye from the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, who shared insights on the advantages of partial nephrectomy, discussed the approaches for robot-assisted partial nephrectomy, and explored the optimization directions for this surgical technique, offering valuable clinical guidance.
2024 COMB丨Dr. Songqing Ye: Exploring the Development of CDK4/6 Inhibitors, ADCs, and Immunotherapy in Early-Stage Breast Cancer

2024 COMB丨Dr. Songqing Ye: Exploring the Development of CDK4/6 Inhibitors, ADCs, and Immunotherapy in Early-Stage Breast Cancer

2024.08.25
From August 2-4, 2024, the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (COMB), organized by the China Cancer Foundation and Beijing Breast Disease Prevention Society, was grandly held in Beijing. The conference brought together the latest advances in individualized precision treatment for breast cancer in China, providing a broad platform for promoting new concepts, developing new technologies, and creating new models in the breast cancer field. With the recent advancements in breast cancer precision medicine, CDK4/6 inhibitors (CDK4/6i), immunotherapy drugs, and antibody-drug conjugates (ADCs) have significantly improved the survival benefits for breast cancer patients. Oncology Frontier conducted an exclusive interview with Dr. Songqing Ye from Fujian Provincial Hospital to discuss the current landscape and trends in the development of new drugs for precision treatment of early-stage breast cancer.
2024 ESMO BC | Exploratory Analysis of the SERENA-2 Study Suggests Early Changes in ctDNA Predict Better Response to Camizestrant Treatment

2024 ESMO BC | Exploratory Analysis of the SERENA-2 Study Suggests Early Changes in ctDNA Predict Better Response to Camizestrant Treatment

2024.08.25
The SERENA-2 study evaluated the efficacy and safety of different doses of Camizestrant (75 mg, 150 mg) compared to fulvestrant in patients with advanced ER+/HER2- breast cancer. The results showed that the median PFS in the Camizestrant groups was similar regardless of ESR1m status or dosage. Researchers further conducted an exploratory analysis of the SERENA-2 study to examine the suppression of ESR1m ctDNA in patients treated with Camizestrant compared to fulvestrant and its correlation with PFS. The findings of this exploratory analysis were presented at the 2024 ESMO BC conference, and this article provides a summary of the results.
JCO | Is It Too Early to Use Radiographic Progression-Free Survival as a Surrogate Endpoint in Metastatic Hormone-Sensitive Prostate Cancer?

JCO | Is It Too Early to Use Radiographic Progression-Free Survival as a Surrogate Endpoint in Metastatic Hormone-Sensitive Prostate Cancer?

2024.08.25
Metastatic hormone-sensitive prostate cancer (mHSPC) is a heterogeneous disease state and represents a critical time window for improving survival in advanced prostate cancer, requiring comprehensive and personalized treatment. As diagnostic and therapeutic strategies continue to advance, the management and assessment of mHSPC have become increasingly complex. Several studies have already evaluated the efficacy of new regimens or drugs for mHSPC using radiographic progression-free survival (rPFS). Recently, a commentary published in the Journal of Clinical Oncology analyzed the feasibility of rPFS as a surrogate endpoint for evaluating mHSPC efficacy. This summary is presented for our readers.